<scp>lncRNA ZEB2‐AS1</scp>: A promising biomarker in human cancers

Mahboobeh, Zarei; Mousavi, Pegah; Fatemeh, Sadri; Karimi, Elham; Azari, Hanieh; Rafat, Milad; Shekari, Mohammad

doi:10.1002/iub.2338

Cited by 18 publications

(15 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some DEirlncRNAs in the 40 IRLP signature have been validated to be involved in the occurrence and development of tumors. lncZEB2-AS1 and MEF2C-AS1 have been demonstrated as poor biomarkers for patients with BRCA [ 24 , 25 ]. Our data indicated those IRLPs are in particular related to MAPK signaling, Jak-STAT signaling, and ErbB signaling pathways in BRCA.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Machine Learning-Devised Immune-Related lncRNA Signature Panel Predicts the Prognosis and Immune Landscape in Breast Cancer Novel IRLP Signature in BRCA

Zhu

Lyu

Wang

et al. 2022

Journal of Immunology Research

View full text Add to dashboard Cite

Long noncoding RNAs (lncRNAs) actively participate in breast cancer (BRCA) tumorigenesis via epigenetic mechanisms. Our study identified immune-related lncRNA (irlncRNA) pairs and compiled them into a set of noncoding gene signatures able to stratify subtypes of BRCA associated with variable degrees of survival and immune cell infiltration. A 40 immune-related lncRNA pair (IRLP) signature including 43 irlncRNAs was built, with high sensitivity and specificity for the prediction of survival in different molecular subtypes of BRCA. Results demonstrated that the low-risk group showed a significantly longer survival rate, and this novel IRLP signature was highly associated with survival status, T stage, metastatic disease, and overall stage in BRCA. Immune infiltrating analyses found that the low-risk group has a lower expression level of macrophage M2 and a higher expression level of immunosuppressed biomarkers than the high-risk group. DEirlncRNAs were further proven to be significantly related to the MAPK signaling, Jak-STAT signaling, and ErbB signaling pathways in BRCA. In conclusion, the 40 IRLP signature showed a promising clinical prediction value in the prognosis of different molecular subtypes and immunotherapy response in BRCA, and the underlying mechanism for these IRLPs warrants further investigations.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Impaired ERBB2 expression or function has been implicated in the progression of breast and gastric cancers [ 26 ], mainly through targeting the PI3K/AKT and MAPK pathways [ 27 ]. Previous studies also demonstrated that some DEirlcnRNAs can modulate those pathways such as lncRNA-ZEB2-AS1 and MEF2C-AS1 [ 24 , 28 ].…”

Section: Discussionmentioning

confidence: 99%

Machine Learning-Devised Immune-Related lncRNA Signature Panel Predicts the Prognosis and Immune Landscape in Breast Cancer Novel IRLP Signature in BRCA

Zhu

Lyu

Wang

et al. 2022

Journal of Immunology Research

View full text Add to dashboard Cite

show abstract

“…and its high expression level has been implicated in many cancers (Guo et al, 2018;Mahboobeh et al, 2020;F. Wu et al, 2019).…”

Section: Discussionmentioning

confidence: 99%

Differential gene expression of BCL‐2, ZEB2‑AS1 and BALR‐2 in prostate cancer and benign prostatic hyperplasia

et al. 2021

View full text Add to dashboard Cite

Prostate cancer (PCa) and benign prostate hyperplasia (BPH) are highly prevalent heterogeneous disorders among men. Whereas PCa and BPH underline common pathological features, apoptotic-related genes might be differentially expressed in these diseases. This study was aimed at testing BCL-2 as well as BALR-2 and ZEB2-AS1 apoptosis-related long non-coding RNA (lncRNA) in patients with PCa and BPH. The expression levels of the BCL-2 gene and ZEB2-AS1 lncRNA were upregulated in tumoural tissues in comparison to adjacent non-cancerous tissues (ANCTs) and BPH tissues. In contrast, the expression level of BALR-2 lncRNA was significantly higher in BPH compared with tumoural tissues. Furthermore, while no association was noticed between the relative expression of ZEB2-AS1 and the tumour grade, the relative expression of BCL-2 and BALR-2 is strongly associated with a higher grade of the tumour in PCa samples compared with the ANCTs. The receiver operating characteristic (ROC) curve analysis indicated the highest specificity and diagnostic value in distinguishing PCa and ANCTs as well as PCa and BPH, respectively. In conclusion, altered expression of BCL-2 and BALR-2 was observed to be associated with tumoural progression and could be used as potential candidates for distinguishing PCa tissues from ANCTs or BPH samples.

show abstract

“…Theragnostics is the nexus point of therapeutics and diagnostics and describes a system to customize healthcare using molecular and genetic tools for treatment decisions tailored to an individual patient [ 159 ]. The emerging functions of many lncRNAs as oncogenes in several carcinomas promoting different steps in carcinogenesis, such as escape to control cellular systems, cell proliferation and migration, aberrant and enhanced metabolism, impaired and deregulated epigenetic landscape, and metastasis, have pointed out lncRNAs as potential therapeutic targets in the breaking of tumorigenesis [ 160 , 161 ]. The importance of lncRNAs in each and every one of these processes has led to the design of different strategies and molecules that allow repressing the function or expression of the lncRNAs, since in most of the examples described, blocking the lncRNA function would be translated in repression of the aggressiveness of cancer accompanied by the reduction of several promoting processes related to carcinogenesis [ 162 ].…”

Section: Development Of Strategies To Obtain the Blocking Oncogene Fu...mentioning

confidence: 99%

Molecular Mechanisms of lncRNAs in the Dependent Regulation of Cancer and Their Potential Therapeutic Use

García-Padilla

Dueñas

García‐López

et al. 2022

IJMS

View full text Add to dashboard Cite

Deep whole genome and transcriptome sequencing have highlighted the importance of an emerging class of non-coding RNA longer than 200 nucleotides (i.e., long non-coding RNAs (lncRNAs)) that are involved in multiple cellular processes such as cell differentiation, embryonic development, and tissue homeostasis. Cancer is a prime example derived from a loss of homeostasis, primarily caused by genetic alterations both in the genomic and epigenetic landscape, which results in deregulation of the gene networks. Deregulation of the expression of many lncRNAs in samples, tissues or patients has been pointed out as a molecular regulator in carcinogenesis, with them acting as oncogenes or tumor suppressor genes. Herein, we summarize the distinct molecular regulatory mechanisms described in literature in which lncRNAs modulate carcinogenesis, emphasizing epigenetic and genetic alterations in particular. Furthermore, we also reviewed the current strategies used to block lncRNA oncogenic functions and their usefulness as potential therapeutic targets in several carcinomas.

show abstract

lncRNA ZEB2‐AS1: A promising biomarker in human cancers

Cited by 18 publications

References 47 publications

Machine Learning-Devised Immune-Related lncRNA Signature Panel Predicts the Prognosis and Immune Landscape in Breast Cancer Novel IRLP Signature in BRCA

Machine Learning-Devised Immune-Related lncRNA Signature Panel Predicts the Prognosis and Immune Landscape in Breast Cancer Novel IRLP Signature in BRCA

Differential gene expression of BCL‐2, ZEB2‑AS1 and BALR‐2 in prostate cancer and benign prostatic hyperplasia

Molecular Mechanisms of lncRNAs in the Dependent Regulation of Cancer and Their Potential Therapeutic Use

Contact Info

Product

Resources

About